Evidence map›Paper›PMID 16133640›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2005

Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Marja Hurley, Wei Yao, Nancy E Lane

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Teriparatide: a novel means to ultimately achieve true regeneration!!!Journal of clinical and diagnostic research : JCDR · 2013
    Article
  8. Review
  9. Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Marja HurleyDivision of Endocrinology and Metabolism, Room AMO47, University of Connecticut School of Medicine, Farmington, Connecticut 06030, USA. hurley@exchange.uchc.edu
Wei Yao
Nancy E Lane
UConn Health · USUniversity of California, Davis · USUniversity of California, San Francisco · US

Funding

Action of Anbolic Factors on Bone Formation in MiceR01AG021189 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI HURLEY, MARJA MARIE · 2004 to 2013
$2.5M
Midcareer Investigator Award Patient-Oriented ResearchK24AR048841 · NIAMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI LANE, NANCY E · 2002 to 2013
$1.4M
CAN PTH REVERSE GLUCOCORTICOID INDUCED OSTEOPOROSIS?R01DK046661 · NIDDK · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI LANE, NANCY E. · 1995 to 2002
$1.1M
NIAMS NIH HHS AR048841-01NIA NIH HHS AG021189NIDDK NIH HHS DK-46661-07
6 · The paper itself

Abstract

Since the ability of parathyroid hormone (PTH) to increase osteoblast maturation and activity is associated with basic fibroblast growth factor (bFGF) we determined the changes in serum bFGF levels in patients treated with human parathyroid hormone (hPTH) (1-34) for 12 months and 12 months follow up. All studied subjects (n=51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n=28), or to a control group (n=23). Osteocalcin (OST), bone-specific alkaline phosphatase (BSAP) and bFGF were monitored at the baseline, every 3 months for 18 months, and at 24 months. In the hPTH group, OST increased by more than 150% above baseline at 3 months and was maintained at this level throughout the treatment period. BSAP had increased more than 80% over the baseline level at 3 months and was maintained at 90% above baseline for the next 9 months. bFGF levels had increased by 45% at 3 months, 60% at 6 to 9 months (P<0.05) and had increased more than 90% from baseline by 12 months (P<0.05). We found that daily hPTH injections increased bFGF levels. These results support the hypothesis that up-regulation of bFGF could play a role in the osteoblastic response to PTH.

Indexed as

Administration, CutaneousAgedAged, 80 and overAlkaline PhosphataseBone DensityBone Density Conservation AgentsDrug Therapy, CombinationEstrogensFemaleFibroblast Growth Factor 2GlucocorticoidsHipHumansLumbar VertebraeMiddle AgedOsteocalcinAlkaline PhosphataseBone Density Conservation AgentsEstrogensFibroblast Growth Factor 2GlucocorticoidsOsteocalcinPrednisoneProgesteroneTeriparatide

Identifiers

PMID16133640
OpenAlexW2096506137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.